Category: pharma

Division Bench of Delhi High Court passed an interim order in Glenmark v. Symed (July 2015)

27th July, 2015 - 7:22 am Categories: India IP Litigation News & Updates patent infringement Patent Litigation Patents pharma Pharma/Biotech Patent Litigations

The High Court of Delhi has passed an interim order wherein the Justices have made it clear that the appellant (Glenmark) may use any other process which may be a development of Glenmark process / Upjohn process so long as it does not infringe the patented processes of the respondent (Symed). Background: Symed Laboratories Ltd. … Continue reading Division Bench of Delhi High Court passed an interim order in Glenmark v. Symed (July 2015)

Read more »

Compulsory Licensing Application against the Patented Drug SAXAGLIPTIN by Lee Pharma

27th July, 2015 - 5:47 am Categories: India IP Practice in India News & Updates Patents pharma

Lee Pharma, a Hyderabad-based Indian pharma company, has filed a Compulsory Licensing (CL) Application (in accordance with Section 84(1) of the Indian Patents Act) against one of the patented drugs Saxagliptin for treating Diabetes Mellitus. The Patent on Saxagliptin was granted to Bristol Myers Squibb (BMS) in India on 30th April 2007 having number IN … Continue reading Compulsory Licensing Application against the Patented Drug SAXAGLIPTIN by Lee Pharma

Read more »

Section 3(D) of Indian Patent Act Strikes Again

27th July, 2015 - 5:24 am Categories: India News & Updates patent infringement Patent Opposition Patents pharma Section 3(D)

India revoked yet another drug patent granted to a German MNC, Boehringer Ingelheim, for its respiratory drug, Spiriva (crystalline tiotropium bromide monohydrate) at a time when the US is putting pressure on the Indian government for not providing adequate patent protection to multinational drug companies. In its decision, the patent office held that Boehringer failed … Continue reading Section 3(D) of Indian Patent Act Strikes Again

Read more »

CIPLA & BMS may settle patent dispute over Entecavir in India

30th May, 2015 - 12:16 pm Categories: IPAB IPAB Decisions News & Updates patent infringement Patents pharma

US based pharma major Bristol-Myers Squibb (BMS) and Indian pharma company Cipla Ltd. are heading towards an amicable settlement on a long-stretched patent dispute concerning BMS’ hepatitis B drug Entecavir, a leading anti-viral drug for Hepatitis B patients that brings in more than a billion dollars each year globally for BMS. Entecavir, being a pre-1995 … Continue reading CIPLA & BMS may settle patent dispute over Entecavir in India

Read more »

Improving Regulatory Transparency for New Medical Therapies Act

9th April, 2015 - 5:11 am Categories: News & Updates Patents pharma

A new act passed in the U.S. house of representative: What will it protect? Patent exclusivity, non-patent exclusivity, or both? Anything else also it deals with? The bill titled ‘A bill to amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to … Continue reading Improving Regulatory Transparency for New Medical Therapies Act

Read more »

Supreme Court stayed the Delhi High Court order of injunction against Glenmark over the Generic drug “Sitagliptin”

2nd April, 2015 - 10:04 am Categories: India IP Litigation IP Practice in India News & Updates patent infringement Patent Litigation Patents pharma Pharma/Biotech Patent Litigations

Reportedly, Hon’ble Supreme Court of India on Special Leave Petition filed by Glenmark stayed the Delhi High Court order which passed injunction against Glenmark for the generic drug Sitagliptin till 28th April 2015. The Delhi high court on dated 20th March 2015 set aside an order of single judge bench of Delhi High Court which … Continue reading Supreme Court stayed the Delhi High Court order of injunction against Glenmark over the Generic drug “Sitagliptin”

Read more »

Recent decision of Delhi High Court in the case of GILEAD PHARMASSET, LLC V. UNION OF INDIA & ANR

23rd February, 2015 - 7:46 am Categories: IP Practice in India News & Updates Patents pharma Section 3(D)

Recently, the Delhi high court on dated 30th January 2015 set aside an order of the Deputy Controller of Patents and Designs. The impugned order rejected a patent to US drug maker Gilead for its hepatitis C drug “Sovaldi” on dated 13th January 2015. Facts of the case: M/S GILEAD PHARMASSET, INC, USA, filed a … Continue reading Recent decision of Delhi High Court in the case of GILEAD PHARMASSET, LLC V. UNION OF INDIA & ANR

Read more »

News Snippet: Novartis sues Cipla for infringement of patents covering “Onbrez”

22nd December, 2014 - 6:27 am Categories: India IP Litigation IP Practice in India News & Updates patent infringement Patents pharma

In a latest update, Novartis has sued Cipla for infringing its patents on “Onbrez” (Indacaterol) after Cipla lunched its generic version for Indacaterol in October claiming “urgent unmet need” for the drug in India. Earlier, as we have reported here, Cipla approached Govt. of India to exercise its statutory powers to revoke the five patents … Continue reading News Snippet: Novartis sues Cipla for infringement of patents covering “Onbrez”

Read more »

CIPLA’s plea for revocation of Novartis Patents for Onbrez may face major set back by the Government

17th December, 2014 - 8:25 am Categories: India IP Litigation IP Practice in India News & Updates Patent Litigation Patents pharma Pharma/Biotech Patent Litigations

As reported in TOI, the Indian Government has found very little merit in Cipla’s plea for waiver and cancellation of Patent rights for chronic obstructive pulmonary disease (COPD) drug over which Novartis has exclusive rights. We have reported on Cipla’s plea here. Background: Cipla, previously approached the Department of Industrial Policy and Promotion (DIPP) to … Continue reading CIPLA’s plea for revocation of Novartis Patents for Onbrez may face major set back by the Government

Read more »

Cipla Files Representation with Govt. Seeking Revocation of Novartis’ Patents

1st November, 2014 - 5:27 pm Categories: India IP Litigation IP Practice in India News & Updates Patent Litigation Patents pharma Pharma/Biotech Patent Litigations

It has been recently reported in Economic times that Cipla has filed representation with the government (Department of Industrial Policy & Promotion) seeking revocation of five patents of Novartis on indacaterol, a respiratory drug for the treatment of chronic obstructive pulmonary disease (COPD) and marketed as Onbrez by Novartis. The central government, under section 66 … Continue reading Cipla Files Representation with Govt. Seeking Revocation of Novartis’ Patents

Read more »

Categories

Archives